CN104147023A - New application of resveratrol derivative - Google Patents
New application of resveratrol derivative Download PDFInfo
- Publication number
- CN104147023A CN104147023A CN201410412210.1A CN201410412210A CN104147023A CN 104147023 A CN104147023 A CN 104147023A CN 201410412210 A CN201410412210 A CN 201410412210A CN 104147023 A CN104147023 A CN 104147023A
- Authority
- CN
- China
- Prior art keywords
- verakanol derivative
- structural formula
- derivative
- verakanol
- molecular structural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a new application of a resveratrol derivative, the resveratrol derivative has hpyerglycemic effect to mice with alloxan diabetes, a molecule structural formula of the resveratrol derivative is as follows, a molecular formula of the resveratrol derivative with the above molecule structural formula is C20H22O9, the molecular weight is 406, degree of unsaturation n is 10, and a name of the is 3'-hydroxy resveratrol, 4'-O-beta-D-pyranoglucoside. According to the resveratrol derivative with the above molecule structural formula, the high purity compound has obvious hpyerglycemic effect to alloxan diabetes, the curative effect is obvious, the resveratrol derivative has no toxicity, no side effect, and is suitable for popularization and application.
Description
Technical field
The present invention relates to a kind of medical technical field, relate in particular to a kind of new purposes of Verakanol derivative.
Background technology
Diabetes are common endocrine metabolism diseases.Along with social development, this disease incidence rate is the trend of rising.Though the chemicals determined curative effect for the treatment of diabetes is also very obvious to the side effect of human body.Though common Chinese medicine toxic and side effects is little, mostly is compound preparation.And the monomeric compound of being originated by natural drug is as the hypoglycemic drug of clinical practice, so far there are no open report.
Summary of the invention
For above problem, the present invention proposes the new purposes that a kind of Verakanol derivative can have obvious hypoglycemic activity.
The present invention is achieved by the following technical solutions:
The new purposes of above-mentioned Verakanol derivative, has hypoglycemic activity to alloxan diabetes mice, and the molecular structural formula of described Verakanol derivative is as follows:
The molecular formula of the Verakanol derivative of above-mentioned molecular structural formula is C20H22O9, and molecular weight is 406, degree of unsaturation n=10, and its name is called 3 '-hydroxyl resveratrol, 4 '-O-β-D-glucopyanoside.
The new purposes of described Verakanol derivative, wherein: the High Purity compound of the Verakanol derivative of described molecular structural formula is that the oral diabetes that mice alloxan is caused of 40mg/kg and 100mg/kg have obvious therapeutical effect at dosage.
The new purposes of described Verakanol derivative, wherein: in the High Purity compound of the Verakanol derivative of described molecular structural formula, the content of effective ingredient is 98%.
The new purposes of described Verakanol derivative, wherein: the Verakanol derivative of described molecular structural formula can be from natural drug as extracted or synthetic Radix Rhei emodi, Rheum hotaoense C. Y. Cheng et C. T. Kao, Rheum officinale, Rheum tanguticum and Rhizoma Polygoni Cuspidati, Radix Polygoni Multiflori Chinese medicine.
Beneficial effect:
The new purposes of Verakanol derivative of the present invention is embodied in, the have hypoglycemic activity of the Verakanol derivative of above-mentioned molecular structural formula to alloxan diabetes mice, the High Purity compound that specifically active constituent content is 98% is that the oral diabetes that mice alloxan is caused of 40mg/kg and 100mg/kg have obvious therapeutical effect at dosage, evident in efficacy and have no side effect, be suitable for propagation and employment.
The specific embodiment
The new purposes of Verakanol derivative of the present invention, its Verakanol derivative relating to can be from natural drug as extracted the Chinese medicines such as Radix Rhei emodi, Rheum hotaoense C. Y. Cheng et C. T. Kao, Rheum officinale, Rheum tanguticum and Rhizoma Polygoni Cuspidati, Radix Polygoni Multiflori, also can synthetic.
The diabetes that Verakanol derivative of the present invention causes mice alloxan have obvious therapeutical effect, and its structural formula is as follows:
The molecular formula of the Verakanol derivative of above-mentioned molecular structural formula is C20H22O9, and molecular weight is 406, degree of unsaturation n=10, and its name is called 3 '-hydroxyl resveratrol, 4 '-O-β-D-glucopyanoside.
Below in conjunction with specific embodiment or experiment diabetes that the Verakanol derivative of the above-mentioned molecular structural formula of the present invention is caused mice alloxan, have obvious therapeutical effect to make further proof:
(1.1) preparation given the test agent
With DDW, make solvent, given the test agent (the High Purity compound of the Verakanol derivative of the above-mentioned molecular structural formula of content 98%) is mixed with respectively to the solution that concentration is 0.5mg/ml, 1.0mg/ml, 2.0mg/ml and 5.0mg/ml;
(1.2) preparation control sample
First by metformin (specification: 0.25g/ sheet) grind into powder, then with 1% tragakanta solution preparation, becoming concentration is 12.5mg/ml suspension;
(1.3) prepare other reagent
Prepare alloxan and glucose assays test kit;
(1.4) preparing experiment equipment
Select 722 grating spectrophotometers, 80-2 centrifugation device and constant temperature water bath;
(1.5) preparing experiment animal
Select the male mice that 90 body weight are 22～24g, be divided into normal group (not modeling, do not give any sample), negative control group (giving normal saline 0.4ml/20g), positive controls (give metformin 250mg/kg, 0.4ml/20g), four dosage group (10mg/kg of High Purity compound, 20mg/kg, 40mg/kg and 100mg/kg; Be 0.4ml/20g).
(1.6) by male mice, the alloxan aqueous solution 0.2ml/10g of the experimental group of all the other except normal group fasting 24h pneumoretroperitoneum injection 200mg/kg causes diabetes model, after 72h, with 0.9～1.1mm blood capillary eye socket venous plexus, get blood, sealing by fusing is not got blood end, under 3500rpm, centrifugal 10min, above operation need complete in 30 minutes;
After centrifugal, get serum, by following test method, operate:
Blank tube: 20ul mixes with enzyme phenol mixed liquor 3ml;
Standard pipe: glucose titer 20ul mixes with enzyme phenol mixed liquor 3ml;
Measure pipe: get serum 20ul and mix with enzyme phenol mixed liquor 3ml;
After each pipe is mixed respectively, put 37 ℃ of water-baths 20 minutes, be chilled to room temperature, 505nm colorimetric, proofreaies and correct " 0 " point with blank tube, reads and respectively manages absorbance, draws as follows each mensuration pipe glucose content:
Picking out the mice of blood sugar concentration more than 11.1mmol/L tests according to blood glucose value height random packet; According to above-mentioned steps (1.5) successive administration 12 days, last administration was again got blood from eye socket venous plexus after 30 minutes and is surveyed blood glucose, and method is the same; The each front palpus of blood sugar concentration fasting 12-16h that surveys; Result of the test, by the statistical test to the difference of change of blood sugar and change percentage in arid, determines whether it has significance.
Below in conjunction with experimental result, the present invention is described further:
As can be seen from the results, normal group blood glucose value remains unchanged substantially; 10 and 20mg/kg group, blood glucose value all has decline, but shows through t assay, with feminine gender group without significant difference; 40mg/kg declines and compares significant difference with matched group with 100mg/kg group blood glucose.Positive controls blood glucose value has been compared significant difference with negative group.
Table 1 is the High Purity compound of Verakanol derivative of the above-mentioned molecular structural formula blood sugar lowering result of the test table to alloxan diabetes mice
With the comparison of feminine gender group:
*p<0.05,
*p<0.01.
Conclusion is, given the test agent 40 and the oral diabetes that mice alloxan is caused of 100mg/kg have obvious therapeutical effect.
The new purposes of Verakanol derivative of the present invention, being embodied in the diabetes that the Verakanol derivative of above-mentioned molecular structural formula causes mice alloxan has obvious therapeutical effect, evident in efficacy and have no side effect, and is suitable for applying.
Claims (4)
1. a new purposes for Verakanol derivative, has hypoglycemic activity to alloxan diabetes mice, and the molecular structural formula of described Verakanol derivative is as follows:
The molecular formula of the Verakanol derivative of above-mentioned molecular structural formula is C20H22O9, and molecular weight is 406, degree of unsaturation n=10, its title 3 '-hydroxyl resveratrol, 4 '-O-β-D-glucopyanoside.
2. the new purposes of Verakanol derivative as claimed in claim 1, is characterized in that: the High Purity compound of the Verakanol derivative of described molecular structural formula is that the oral diabetes that mice alloxan is caused of 40mg/kg and 100mg/kg have obvious therapeutical effect at dosage.
3. the new purposes of Verakanol derivative as claimed in claim 2, is characterized in that: in the High Purity compound of the Verakanol derivative of described molecular structural formula, the content of effective ingredient is 98%.
4. the new purposes of Verakanol derivative as claimed in claim 1, is characterized in that: the Verakanol derivative of described molecular structural formula can be from natural drug as extracted or synthetic Radix Rhei emodi, Rheum hotaoense C. Y. Cheng et C. T. Kao, Rheum officinale, Rheum tanguticum and Rhizoma Polygoni Cuspidati, Radix Polygoni Multiflori Chinese medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412210.1A CN104147023A (en) | 2014-08-20 | 2014-08-20 | New application of resveratrol derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412210.1A CN104147023A (en) | 2014-08-20 | 2014-08-20 | New application of resveratrol derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104147023A true CN104147023A (en) | 2014-11-19 |
Family
ID=51872788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410412210.1A Pending CN104147023A (en) | 2014-08-20 | 2014-08-20 | New application of resveratrol derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104147023A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294912A (en) * | 1999-11-05 | 2001-05-16 | 中国人民解放军军事医学科学院放射医学研究所 | Blood sugar reducing compound |
-
2014
- 2014-08-20 CN CN201410412210.1A patent/CN104147023A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294912A (en) * | 1999-11-05 | 2001-05-16 | 中国人民解放军军事医学科学院放射医学研究所 | Blood sugar reducing compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836195B (en) | The Kunlun snow chrysanthemum extract and uses thereof | |
| CN103893258A (en) | Oral solid preparation containing desmodium styracifolium general flavone and application thereof | |
| CN1680355A (en) | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN104474236B (en) | A kind of Chinese medicine for the treatment of flu and preparation method thereof | |
| CN104147023A (en) | New application of resveratrol derivative | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| CN102240328B (en) | Traditional Chinese medicine for treating cold and preparation method thereof | |
| CN104382973B (en) | Asarum total volatile oil extract and extracting method and the purposes in treatment chronic cough medicine is prepared | |
| CN101084951B (en) | Medicine for treating diseases concerned with respiratory and preparation method and application thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN102614222A (en) | Sea cucumber extract rich in triterpene sapogenin and preparation method and application thereof | |
| CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
| CN105998049A (en) | Application of dendrobium polysaccharides in preparation of medicines and health products for preventing and treating metabolic syndrome | |
| CN106138054A (en) | Chelerythrine application in treatment fowl drug resistance colibacillosis | |
| CN103142597B (en) | Ipecacuanha effective component composition, its preparation method and application | |
| WO2021128234A1 (en) | Radix ophiopogonis degradation extract and application thereof in preparation of drugs for prevention and treatment of cardiovascular diseases | |
| Dasgupta | Toxic herbals and plants in the United States | |
| CN105434886A (en) | Dendrobium officinale root extractive with blood-sugar reducing effect and uses thereof | |
| CN103356813B (en) | Indian stringbush root capsule | |
| CN108159218A (en) | A kind of preparation method of two old extracts and its preparation with antitumor activity | |
| CN101966251B (en) | Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof | |
| CN100500158C (en) | Aspirin slow-release tablet and its preparation method | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141119 |
|
| RJ01 | Rejection of invention patent application after publication |